Post-event Report - TIDES: Oligonucleotide and Peptide Therapeutics

In September 2020, the first virtual TIDES: Oligonucleotide and Peptide Therapeutics conference took place, delivering over 175 presentations and discussions exploring a diverse range of topics across the spectrum of oligonucleotide and peptide therapeutics.

This year's agenda included topics including preclinical, CMC and drug delivery strategies, COVID-19 and pandemic responses, while also sporting a brand new stream on partnering in the industry.

We’ve put together a report, providing a summary of the key themes, highlights and hottest topics across live keynotes, panel discussions on-demand presentations and posters.

The report features:

1. Key Themes of The Event - Executive Summary - Biotech researcher and writer Dr. Catarina Carrao reflects on the main themes of the event, explored through top keynotes and panel sessions, in this executive summary.
2. Top Keynote Presentation: Tuning siRNA Potency, Specificity and Distribution through Chemistry - Prof. Anastasia Khvorova, Professor at University of Massachusetts Medical School detailed the methods of optimizing siRNAs within the chemistry process in a keynote session and Q&A.
3. Hot Topic Keynote Presentation: mRNA as Medicine - In an exciting keynote, Dr. Melissa Moore, Chief Scientific Officer, Moderna Therapeutics, Inc. revealed the latest uses of messenger RNA in drug and vaccine development.
4. Poster: A Universal Method for the Quantitation of Multiple Oligonucleotides from Plasma by MFLC-MS/MS - This popular poster and presentation by Chad Christianson, Senior Principal Scientist at Alturas Analytics, describes a method of bioanalysis of oligonucleotides which shows numerous benefits over ELISA and qPCR.
5. On-demand Session: Oligonucleotide Manufacturing Capabilities at Ajinomoto Bio-Pharma Services - Soichi Utsumi, General Manager of Sales at Aji Bio-Pharma Osaka, introduced the leading oligo capabilities and novel technologies at Ajinomoto Bio-Pharma.
6. On-demand Session: An Approach to Process Validation for Peptides: Applying Bachem CMC concept to (Nle3)-Angiotensin I/II validation, a case study - Matteo Villain, Ph.D., Vice President, CMC Development at Bachem Americas, Inc. describes the company's approach to Process Design and Process Qualification of peptidic API as demonstrated in a case study for (Nle3)-Angiotensin I/II validation.

Whether you attended the event, or you'd just like to find out more, we invite you to join us as we look back at the best parts of the week.

Click the image at the top of the page or here to explore the report.